Core Viewpoint - The research highlights the role of mitochondrial RNA (mtRNA) in activating the immune system during chemotherapy and identifies the PNPT1 protein as a key regulator in overcoming therapeutic resistance in cancer treatment [4][16]. Group 1: Mechanism of Immune Activation - Chemotherapy activates the immune system by releasing "danger signals" such as nuclear DNA, which triggers the cGAS-STING immune pathway [6]. - The new study reveals that chemotherapy also prompts mitochondria to release mitochondrial double-stranded RNA (mt-dsRNA), activating the MAVS pathway, a more universal immune response mechanism [6][5]. Group 2: Tumor Resistance Mechanism - Tumor cells counteract immune activation by upregulating PNPT1, a protein that degrades mitochondrial RNA, effectively destroying the "danger signals" before they can activate the immune system [8][9]. - High levels of PNPT1 in various cancers correlate with poor patient prognosis and weaker immune responses, contributing to chemotherapy and immunotherapy resistance [9][8]. Group 3: Proposed Treatment Strategy - The research proposes a combined treatment strategy: 1. "Internal" approach - Inhibiting PNPT1 using Lanatoside C, an FDA-approved drug, to allow the production of "danger signals" [10]. 2. "External" approach - Using BH3 mimetics to open channels in the mitochondrial membrane, facilitating the release of mt-dsRNA into the cytoplasm [10]. - The combination of these two approaches has shown significant synergistic effects in mouse tumor models, inhibiting tumor growth and extending survival [13]. Group 4: Significance and Future Prospects - This research offers new hope for cancer patients facing treatment resistance, suggesting that the combined approach could lead to breakthroughs in cancer therapy [15]. - The identification of PNPT1 as a target for overcoming immune evasion provides a new avenue for therapeutic development, with the potential for faster clinical translation due to the use of existing drugs [16].

结直肠癌 ： QKI 蛋白通过调控 PABPN1 的液-液相分离影响 RNA 加工，其低表达与癌细胞增殖相关； FOXC1 介导丝氨酸代谢重编程，激活 ERK1/2 通路促进 5-FU 耐药，联合丝氨酸限制与靶向治疗或为新策 略。 三阴性乳腺癌 （TNBC） ：天然化合物 Pristimerin 靶向 HSPA8 激活 VAV1/ERK 通路，诱导自噬与凋亡，抑 制转移并增变化疗敏感性；BCA2 通过 TLR4/NF-κB 通路上调 SOX9，促进干细胞特性，为克服耐药提供新 靶点。 这些研究从分子机制到治疗策略层层突破，为两类癌症的精准医疗提供了创新思路。 文献 分享 一 论文题目 ： BiFC and FACS-based CRISPR screening revealed that QKI promotes PABPN1 LLPS in colorectal cancer cells （BiFC 和 FACS-based CRISPR 筛选揭示 QKI 促进 PABPN1 的液- 液相分离） 期刊名 ： Protein & Cell 结直肠癌 与 乳腺癌 作为全球高发恶性肿瘤，其发病机制复杂且治疗需求迫 ...